Frequent expression of CD30 antigen in the primary gastric non-B, non-Hodgkin lymphomas
Frequent expression of CD30 antigen in the primary gastric non-B, non-Hodgkin lymphomas
复制标题
DOI：
10.1111/j.1440-1827.2004.01657.x
复制
发表时间：
2004-07-01
影响因子：
2.2
通讯作者：
Mori, N
中科院分区：
文献类型：
--
作者：
Iwamizu-Watanabe, S;Yamashita, Y;Mori, N
大多数原发性胃淋巴瘤是B细胞起源的。本文报告14例胃原发性非B、非霍奇金淋巴瘤的临床病理和免疫表型。这些病例包括11名男性和3名女性，中位年龄为56.5岁。大多数患者接受手术或化疗，显示5年生存率为57.5%。形态学上，肿瘤细胞具有多种组织学特征，如间变性大细胞淋巴瘤（ALCL）（n = 3），外周T细胞淋巴瘤，未特别指明的大细胞淋巴瘤（n = 4），中等细胞淋巴瘤（n = 2）和混合细胞淋巴瘤（n = 5）。2例显示非B、非T细胞表型，而其余病例显示T细胞表型。CD 4 + 6例，CD 8 + 2例。10例肿瘤细胞为CD 30+。6例TIA-1呈阳性。在1例病例中，通过免疫染色确定了间变性大细胞淋巴瘤激酶（ALK），并通过荧光原位杂交（FISH）检测了ALK的染色体重排。总之，尽管CD 30的表达机制尚不清楚，但原发性胃非B、非霍奇金淋巴瘤倾向于表达CD 30。我们认为本研究中的一些病例可能来源于细胞毒性T细胞，类似于全身性和皮肤ALCL，其中大多数表现为TIA-1。
Most primary gastric lymphomas are of B-cell origin. Fourteen cases of primary gastric non-B, non-Hodgkin lymphomas were studied to evaluate their clinicopathological and immunophenotypic findings. The cases were comprised of 11 men and three women, with a median age of 56.5 years. Most patients underwent surgery either with or without chemotherapy, exhibiting a 5 year survival rate of 57.5%. Morphologically, the neoplastic cells showed various histological features, such as anaplastic large cell lymphoma (ALCL) (n = 3), peripheral T-cell lymphoma, unspecified, large (n = 4), medium-sized (n = 2) and mixed cell (n = 5). Two cases displayed a non-B, non-T cell phenotype, whereas the remaining cases displayed a T-cell phenotype. Six cases were CD4+, while two were CD8+. The neoplastic cells were CD30+ in 10 cases. TIA-1 was positive in six cases. In one case, anaplastic large cell lymphoma kinase (ALK) was identified with immunostaining and chromosomal rearrangement of ALK was detected by fluorescence in situ hybridization (FISH). In conclusion, although the mechanism of CD30 expression is unknown, primary gastric non-B, non-Hodgkin lymphomas tend to express CD30. We consider that some of the cases in the present study may be derived from cytotoxic T cells, similar to systemic and cutaneous ALCL, the majority of which exhibit TIA-1.